ReviewTherapeutic advances in gastroenterology2026
Clinical diagnosis and biomarkers of acute kidney injury in liver cirrhosis: a systematic review.
Review in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overview of pseudo-acute kidney injury.Renal failure · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute kidney injury (AKI) in cirrhotic patients is associated with high morbidity and mortality. Serum creatinine (sCr) has limited utility for early detection and etiological differentiation. Novel biomarkers and predictive models offer potential to address these limitations. Objectives: To comprehensively evaluate the diagnostic performance of novel biomarkers and predictive models for the early detection and etiological differentiation of AKI in patients with liver cirrhosis. Design: Systematic review conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. Data sources and methods: A comprehensive literature search was performed in Results: A total of 33 studies were included. For the early prediction of AKI, serum cystatin C (Cys C) demonstrated superior performance to sCr, with an area under the receiver operating characteristic curve (AUROC) of up to 0.85. Urinary neutrophil gelatinase-associated lipocalin (NGAL) exhibited strong predictive capability and was most reliable in differentiating acute tubular necrosis from hepatorenal syndrome (HRS), achieving an AUROC up to 0.87. In contrast, kidney injury molecule-1, interleukin-18, and liver-type fatty acid binding protein, showed only moderate or inconsistent performance across most studies. Seven studies developed predictive models by integrating clinical variables with biomarkers, some of which employed machine learning techniques. However, the clinical applicability of these models is currently constrained by significant heterogeneity and limited external validation. Conclusion: Serum Cys C and urinary NGAL offer distinct advantages over sCr in the early diagnosis and phenotypic differentiation of AKI. Although prediction models show promise, their routine clinical application requires further standardization and extensive external validation. Trial registration: PROSPERO (CRD420251126410).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.